{"id":689224,"date":"2022-09-27T08:35:01","date_gmt":"2022-09-27T12:35:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"modified":"2022-09-27T08:35:01","modified_gmt":"2022-09-27T12:35:01","slug":"imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","title":{"rendered":"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>LAWRENCEVILLE, N.J., Sept.  27, 2022  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <strong>Imunon<\/strong><br \/>\n        <strong>, Inc.<\/strong><br \/>\n        <strong>\u00a0(NASDAQ: <\/strong><br \/>\n        <strong>IMNN<\/strong>), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1&#215;1 meetings at the upcoming Chardan 6<sup>th<\/sup> Annual Genetic Medicines Conference. The conference will be held on October 3-4 with in-person participation held at the Westin Grand Central Hotel in New York City.<\/p>\n<p align=\"justify\">Dr. Le Goff will present in person on Monday, October 3<sup>rd<\/sup> at 2:30 pm ET. The presentation will available live and on-demand <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yzdf88azPoap90BS4aI3vtxsXbHQxor0sImrLwqQsR5P8c2ffBEL6j_pddOGKGmrTjxSduBuqSY6OFmUEcCnrQhw41EdCNiqdfTN5KDoFxQ=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0<\/strong><br \/>\n        <strong>Imunon<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong> Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body\u2019s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.<\/p>\n<p align=\"justify\">Imunon has two platform technologies: Our TheraPlas<sup>\u00ae<\/sup> platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company\u2019s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate its PLACCINE platform. Imunon\u2019s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. The Company will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions. For more information on Imunon, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CjA68jAabObbi__G84gmgoqsA1EqBCP71Ei7KY4lpWNR3Whw3pfKacVeymXzVnBS\" rel=\"nofollow noopener\" target=\"_blank\"><u>ww<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-8STo-T7WAvKSQ_jyP8cJmKPeTl28pJE7-b6cBmsZiKmHXkV3ROORiKc3b7fiOQ7\" rel=\"nofollow noopener\" target=\"_blank\"><u>w<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bDhRwN3X0RpnurTUSRzyOn3D4bAZTVWtLiorncpsJ25kWcOXsxcRecb-Tn2voRbLOI7wm0gEwJf_M9ZQS69UzQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>.imunon.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Imunon<\/em><br \/>\n        <em> wishes to inform readers that forward-looking statements in this news release are made pursuant to the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for <\/em><br \/>\n        <em>Imunon<\/em><br \/>\n        <em> to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in <\/em><br \/>\n        <em>Imunon\u2019s<\/em><br \/>\n        <em> periodic reports and prospectuses filed with the Securities and Exchange Commission. <\/em><br \/>\n        <em>Imunon<\/em><br \/>\n        <em> assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">Jeffrey W. Church<br \/>Executive Vice President, CFO and Corporate Secretary<br \/>609-482-2455<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fq_tPcYLaIdCEbGKeVE5gTHpMXX0HZVm_JwbFDb6WA_uErr0g8DqwZTh5lDAQrTKqeK84MJfzYr98YpmZcxl4A==\" rel=\"nofollow noopener\" target=\"_blank\"><u>jchurch@imun<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rw6nMLb_1Iyg_zYKLky7hOoZl81nVAfKhNo-BgWdCqXyOq6EBNIaRP-RmRaqoMLi\" rel=\"nofollow noopener\" target=\"_blank\"><u>o<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=22G7pTGrYNpiEBU4NrISdQHfAqRiv8cYiifISQCQAox8TxnfLO0i2HJ7GnMa45qC\" rel=\"nofollow noopener\" target=\"_blank\"><u>n<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GmmjZGgoLZaR9_YW6NianmHD7zbo221dyFezm1eA33KpYKGE_qopWc3rWSgS_vuRMQkSlg0W72EGouAGxWAdog==\" rel=\"nofollow noopener\" target=\"_blank\"><u>.com<\/u><\/a><\/p>\n<p align=\"justify\">LHA Investor Relations<br \/>Kim Sutton Golodetz<br \/>212-838-3777<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_eWGHH8KmdZ9O1MUtEIWw7Z-b96lCKPd4vyCXyfz3gvaygO5fYrdHRRK5VEhOhpdYkEC34nnug8tRl6tgQdcfRLZuAagOOjkUa88QyHRYMk=\" rel=\"nofollow noopener\" target=\"_blank\">kgolodetz@lhai.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjIyNTlhN2EtNDJmNS00NjdhLThiZTEtNmMwZWYwOWQxNDg1LTUwMDA0OTc3Ng==\/tiny\/Imunon-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Imunon , Inc. \u00a0(NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1&#215;1 meetings at the upcoming Chardan 6th Annual Genetic Medicines Conference. The conference will be held on October 3-4 with in-person participation held at the Westin Grand Central Hotel in New York City. Dr. Le Goff will present in person on Monday, October 3rd at 2:30 pm ET. The presentation will available live and on-demand here. About\u00a0 Imunon , Inc. Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689224","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Imunon , Inc. \u00a0(NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1&#215;1 meetings at the upcoming Chardan 6th Annual Genetic Medicines Conference. The conference will be held on October 3-4 with in-person participation held at the Westin Grand Central Hotel in New York City. Dr. Le Goff will present in person on Monday, October 3rd at 2:30 pm ET. The presentation will available live and on-demand here. About\u00a0 Imunon , Inc. Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body\u2019s &hellip; Continue reading &quot;IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T12:35:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\",\"datePublished\":\"2022-09-27T12:35:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"wordCount\":501,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"name\":\"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==\",\"datePublished\":\"2022-09-27T12:35:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","og_locale":"en_US","og_type":"article","og_title":"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","og_description":"LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Imunon , Inc. \u00a0(NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1&#215;1 meetings at the upcoming Chardan 6th Annual Genetic Medicines Conference. The conference will be held on October 3-4 with in-person participation held at the Westin Grand Central Hotel in New York City. Dr. Le Goff will present in person on Monday, October 3rd at 2:30 pm ET. The presentation will available live and on-demand here. About\u00a0 Imunon , Inc. Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body\u2019s &hellip; Continue reading \"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-27T12:35:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference","datePublished":"2022-09-27T12:35:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"wordCount":501,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","name":"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==","datePublished":"2022-09-27T12:35:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzQxMyM1MTcyMDk5IzUwMDA0OTc3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMUNON to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689224"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689224\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}